IGFBP1 Antibody (H-5): sc-55474

IGFBP1 Antibody (H-5) is a mouse monoclonal IgG1 kappa light chain antibody that detects IGFBP1 in mouse, rat, and human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). IGFBP1 (H-5) antibody is available in both non-conjugated and multiple conjugated forms, such as agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and various Alexa Fluor® conjugates. Insulin-like growth factor-binding proteins (IGFBPs) are crucial regulators of the IGF signaling system, and IGFBP1 plays a significant role in modulating IGF bioavailability by binding and influencing distribution in the extracellular environment. IGFBP1 regulation is particularly important as insulin production negatively regulates IGFBP1, making IGFBP1 a key player in metabolic processes and fetal development. IGFBP1 gene expression is notably high during fetal liver development and responds to nutritional changes and diabetic conditions, highlighting IGFBP1′s importance in growth regulation and metabolic health. IGFBP1 interacts with other IGFBPs, such as IGFBP2, which may function as a chaperone for IGFs, and IGFBP3, the most abundant IGFBP that complexes with a significant portion of serum IGFs. Understanding IGFBP1 dynamics and interactions is essential for elucidating IGFBP1′s role in growth regulation and potential implications in various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IGFBP1 Antibody (H-5) References:

1. Profound changes in the GH-IGF-I system in adolescent girls with IDDM: can IGFBP1 be used to reflect overall glucose regulation?  |  Halldin, MU., et al. 2000. Pediatr Diabetes. 1: 121-30. PMID: 15016222
2. Improved glycemic control due to sitagliptin is not related to cortisol or the surrogate marker IGFBP-1 for hepatic insulin sensitivity.  |  Arnetz, L., et al. 2015. Growth Horm IGF Res. 25: 298-303. PMID: 26283275
3. HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1.  |  Faxén, UL., et al. 2017. J Card Fail. 23: 293-303. PMID: 27327968
4. Adiponectin, IGFBP-1 and -2 are independent predictors in forecasting prediabetes and type 2 diabetes.  |  Brismar, K., et al. 2022. Front Endocrinol (Lausanne). 13: 1092307. PMID: 36686443
5. Insulin-like growth factor binding proteins as glucoregulators.  |  Baxter, RC. 1995. Metabolism. 44: 12-7. PMID: 7476305
6. Structure and localization of the IGFBP-1 gene and its expression during liver regeneration.  |  Lee, J., et al. 1994. Hepatology. 19: 656-65. PMID: 7509771
7. Insulin-like growth factors.  |  Schmid, C. 1995. Cell Biol Int. 19: 445-57. PMID: 7640658
8. The IGF system in metabolism regulation.  |  Binoux, M. 1995. Diabete Metab. 21: 330-7. PMID: 8586149
9. Differential expression of IGFBPs by normal and hypertrophic scar fibroblasts.  |  Hathaway, CL., et al. 1996. J Surg Res. 60: 156-62. PMID: 8592408
10. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics.  |  Kelley, KM., et al. 1996. Int J Biochem Cell Biol. 28: 619-37. PMID: 8673727
11. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II.  |  Oh, Y., et al. 1996. J Biol Chem. 271: 30322-5. PMID: 8939990
12. IGFBP1 and Follistatin-like 3 genes are significantly up-regulated in expression profiles of the IUGR placenta.  |  Okamoto, A., et al. 2006. Placenta. 27: 317-21. PMID: 16338475

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IGFBP1 Antibody (H-5) has 16 citations in a variety of scientific publications.

Primary antibodies like Anti-IGFBP1 Antibody (H-5) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IGFBP1 Antibody (H-5) Specifications

Alternate Product Name: IGFBP1

Product Clone Name: H-5

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 121-240

Epitope Target: IGFBP1

Epitope Species: human

Product Reactivity/Detection: IGFBP1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 16 citations in various scientific publications

Available Conjugates/Forms for IGFBP1 Antibody (H-5): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin